1768 East 25th Street Suite 301 Cleveland, OH 44114 216.367.0602

egeneration.org

Advances in Medical Isotopes

Pursuing and Providing Cures for Cancer and other Terminal Illnesses

TABLE OF CONTENTS

Medical Radioisotopes ...................................................................................................................................................... 1

Molten Salt Reactors (MSRs) ......................................................................................................................................... 2

The Economic Impact of Radioisotopes ...................................................................................................................... 3

Molybdenum 99 Production ........................................................................................................................................... 3

Radioisotopes Used for Therapy ................................................................................................................................... 4

Radioisotopes and Cancer Treatment .......................................................................................................................... 4

Radioisotopes and HIV AIDS ......................................................................................................................................... 5

Copyright © 2015 by eGeneration Foundation

All rights reserved

Advances in Medical Isotopes | 1

MEDICAL RADIOISOTOPES Isotopes are atoms with the same number of protons but differing numbers of neutrons. Isotopes

are different forms of a single element. Radioisotopes are radioactive isotopes. Radioisotopes are widely used in industry, medicine, and scientific research. A very specific radioisotope is used in millions of important medical imaging regimens each year. Other isotopes are required for certain types of cancer research and some may be used in new types of cancer therapy. There currently are supply problems for these important isotopes, but a solution exists: they can be produced in a certain type of advanced nuclear reactor, a Molten Salt Reactor (MSR). How these reactors work, and why they are particularly well suited to alleviate these isotope shortage problems, will be described below.

Molybdenum-99 (99Mo) is a radioactive isotope of the element molybdenum, whose decay product, technicium-99, is used extensively in nuclear medicine imaging. As such, a reliable supply of 99Mo is a necessity for modern cancer treatment. Unfortunately, the supply of 99Mo is now being threatened because of political and economic factors.

First, most of the world's supply of 99Mo comes from outside the United States where it is made in research and test reactors that use highly enriched uranium (HEU) targets. The HEU is provided by the United States. Under a 2013 U.S. law, the U.S. must cease exporting HEU by the year 2020. It will begin to phase out export of HEU because of fear that this material could fall into the hands of organizations that would use it to construct weapons. As a result of this mandate, foreign reactors, should they remain operational at all, will be forced to use less efficient low-enriched uranium for isotope-making targets, thereby reducing the 99Mo supply here in the U.S.

Second, many of the reactors that do produce 99Mo are now aging to the point that they no longer function reliably. As an overall result, 99Mo production continues to decrease and, on occasion, has stopped completely for short periods of time. There is every reason to believe that without significant financial intervention, the supply of 99Mo will continue to decrease, which will degrade the effectiveness of cancer treatment. Clearly, this is unacceptable.

In the United States there are currently no major suppliers of 99Mo for medical imaging use, although that same 2013 law requires that the U.S. become self-sufficient in producing it. Reactors and cyclotrons could be built for production of 99Mo, but a much better solution would be the construction of a few small, multipurpose, liquid-fueled, Molten Salt Reactors (MSRs). Just a few of these MSRs could produce sufficient 99Mo to meet the country’s needs, and this would satisfy Congressional legislation mandating domestic, affordable, and proliferation-resistant radioisotope supplies for medical use. Such reactors, optimized for enhanced radioisotope production, would provide a commercial product worth billions of dollars, while eliminating the risk of theft of high-enriched uranium targets.

Advances in Medical Isotopes | 2

MOLTEN SALT REACTORS (MSRS) A Molten Salt Reactor (MSR) is a type of nuclear fission reactor which uses molten salt rather

than high-pressure water as its primary coolant; in its modern form this coolant is the liquid fuel itself. The use of molten salt allows the MSRs to run at higher temperatures than conventional water-cooled reactors, making them more efficient, and because there is no need for a pressure dome, far safer. For example should the plant begin to overheat due to a natural disaster or serious malfunction, the liquid fuel automatically drains from the core, which will bring the nuclear reaction to a halt.

Of particular interest to us are MSRs of the type known as liquid fluoride thorium reactors (LFTRs — pronounced “lifters”) that use, as fuel, the plentiful metallic element thorium dissolved in a fluoride-based molten salt. A discussion of the many technical advantages of LFTRs over currently used light water reactors is beyond the scope of this monograph, but one striking advantage of LFTRs is that they produce copious amounts of 99Mo as a byproduct. In addition, these LFTRs uniquely provide the radioisotopes Actinium-225 and Bismuth-213 — currently all but unobtainable — which have the potential to be used in new types of cancer treatment now being developed (described below).

The decay scheme of the element thorium

The isotopes shown in yellow are of significant

medical interest

Advances in Medical Isotopes | 3

THE ECONOMIC IMPACT OF RADIOISOTOPES Historically there had been a debate in the nuclear industry as to which was more valuable;

income streams from the electric power produced by nuclear power plants or profits from the by-products of their operation (stable and radioactive isotopes and nuclear materials.) Among the industry experts the opinion prevailed that nuclear reactors made the most money from electric power production. It turns out substantially more economic activity is created from isotope production.

In the early nineties, the U.S. Council for Energy Awareness, the USCEA, commissioned detailed research of the income streams of nuclear power and isotope and material technologies on the national economy (excluding the military). The final report surprised the entire industry. The total annual revenue connected with radioisotope applications in the United States was $257 billion dollars in 1991. This was three and half times more than that earned from production of nuclear electric power ($73 billion).

In addition, 3.7 million people in almost five hundred specialties were employed either directly or indirectly in radioisotope and nuclear materials industries. Together, these industries account for about three percent of full employment in the U.S.

Production of medical radioisotopes has become the most important sector of the nuclear industry, accounting for more than 50% of annual radioisotopes production worldwide. Today more than 160 radioisotopes of 80 chemical elements are produced for use in diagnosis and therapy of cancer, as well as cardiology, hematology, urology, nephrology, and other specialties.

MOLYBDENUM 99 PRODUCTION Molybdenum 99 (99Mo) is one of the radioisotopes in greatest demand. It is used in 99Mo/99mTc

(metastable Technetium-99) generators widely used in diagnostic scans for cancer and cardiovascular diseases; the diseases that are the leading cause of death in Americans. More than 80% of radio-diagnostic procedures in the world are carried out by preparations labeled with 99m�c, according to IAEA (International Atomic Energy Agency) reports. Currently, about 30 million diagnostic procedures are carried out worldwide annually with 99mTc; world consumption of 99Mo /99mTc has exceeded 12,000 curies per week at a cost of $3.7 billion. About 95% of 99Mo production happens in Canada, the EU and South Africa.

As recently as 2012, there was a series of unplanned stoppages of the reactors producing 99Mo, mainly due to the aging of these reactors; this demonstration of the imperfection of the existing system of supplying this vital isotope has caused growing concern for the future of nuclear medicine. These problems in 99Mo production had a negative effect on treatment of oncologic patients in Europe and

Advances in Medical Isotopes | 4

Northern America. For example, during these shortages, supply of 99Mo /99mTc generators in some British hospitals was reduced by 30% from normal. For the duration of the shortage, the doctors had to choose which patients most needed 99mTc-based procedures.

In addition to the 99Mo, other diagnostic radioisotopes used by the medical community can be processed efficiently by LFTRs. These include 89Sr, 133Xe, 131I, and 90Y. For example, recovery of Sr-89 is about 1000 times more efficient from a LFTR compared to solid-target-irradiation of Sr-88.

RADIOISOTOPES USED FOR THERAPY Actinium-225 (225Ac) has a half-life of 10 days; during its decay it emits four alpha particles for

every disintegrated atom. Thus a milligram of 225Ac emits about a million trillion alpha particles during this time. As described below, even a single alpha particle will kill a cancer cell if it is close enough to it.

This radioisotope is currently only available as a consequence of rare radioactive decays. However, 225Ac is produced in large amounts in a LFTR, so production of this radioisotope for cancer research becomes one of the rationales for developing LFTR technology.

Bismuth-213 (213Bi) decays with a half-life of only 45.6 minutes, to 209Bi (stable), during which, it emits one alpha particle. As is the case for 225Ac, a LFTR is the only practical way of producing this isotope in reasonable quantities.

RADIOISOTOPES AND CANCER TREATMENT Cancer is one of the main health problems of today. While the treatment for some cancers has

been very successful, improvements over the years for others has been much more modest. A particularly difficult situation occurs in so-called Stage IV disease where the primary cancer has spread or metastasized throughout the body. Although chemotherapy, hormonal therapy, and targeted agents can definitely prolong life in those situations, outright cures are unusual. New therapeutic approaches are therefore definitely needed.

Targeted Alpha Therapy (TAT) is a possible new approach to treating such patients. TAT is based on the coupling of an alpha-emitting radioisotope to a tumor selective carrier, usually an antibody. These antibodies recognize tumors through tumor-specific antigens (proteins) that are expressed on the tumor cell surface, and can bind selectively to these cells, similar to a key fitting into a lock. In TAT these carrier antibodies serve as vehicles to transport the radioisotopes to the cancer cells.

Radioisotopes that emit alpha particles seem particularly promising to selectively destroy cancer cells. Alpha particles have a high energy, in the range of 5-9 MeV, and discharge that energy along a very

Advances in Medical Isotopes | 5

short path length. In human tissue this length is typically less than 0.1 mm, corresponding to just a few cell diameters. It has been shown that just a single alpha particle striking a cell nucleus can shatter the cell’s DNA beyond repair, utterly destroying the cell, and even tiny amounts of alpha-emitting radioisotopes emit trillions of alpha particles each second. But if the alpha emitter is not stuck tightly against a cell, all these alpha particles will be stopped harmlessly by the fluid and connective tissue between cells, and rendered harmless. So the only cells that are killed are those that are directly bound to the antibody.

Many technical problems need to be overcome before such a scenario can be used for cancer therapy, not least that manufacturing tumor-specific antibodies is a very difficult task. Still, some progress is being made in this area, and the routine use of highly pure (monoclonal) antibodies, with or without radioactive attachments has become routine in the treatment of lymphoma. Importantly for our purpose here, studies looking at the value of attaching alpha emitters to such antibodies are hampered by a lack of suitable radioisotopes such as Actinium-225 and Bismuth-213. Both of these are byproducts of a LFTR, but they are not easily obtainable in any other way.

TAT may also be suitable to prepare leukemia patients for bone marrow transplants. Linked to an antibody (CD-45) which binds mainly to bone marrow cells of all types, it can, theoretically, destroy a patient’s bone marrow that harbors large amounts of leukemia and prepare it for a bone marrow transplant. Currently this must be done with high doses of chemotherapy that also destroy the marrow, but can damage the rest of the patient. Current studies are underway to determine the effectiveness of this procedure.

RADIOISOTOPES AND HIV AIDS In a manner similar to that described above, TAT might also be useful for eliminating HIV

infected cells that express viral antigens on their surfaces that are not killed by HIV antiviral medications. The goal here would be to “complete the cure” that cannot quite be done with medication alone.

This hypothesis, that HIV infected cells could be killed by an alpha-emitting radioisotope, has been successfully tested, and these results provide support for the concept that these antibodies labeled with radioactive substance (Bi-213) can be used for treatment of HIV. Pre-clinical development testing the efficacy and safety of this novel therapy approach are being undertaken in preparation of a Phase I clinical trial in HIV infected patients.

Advances in Medical Isotopes | 6

SUMMARY As you can see, the need for these critical radioisotopes is urgent. The potential to save lives is

obvious, and the opportunity to help all of humanity is within our grasp. We must not wait as lives hang in balance. Developing the technologies outlined in this document will bring much needed resources to the medical field.

1768 East 25th Street Suite 301 Cleveland, OH 44114 216.367.0602

eGeneration.org

The  eGeneration  Foundation  is  a  501(c)3  non-­‐profit  educational  charity.  

Your  contribution  to  the  eGeneration  Foundation  is  tax-­‐deductible  as  a  charitable  contribution  to  the  extent  allowed  by  law.

Your support is greatly appreciated! Please contact us today!